News
Systematic benefit-risk study deems remdesivir a ‘favourable’ COVID-19 treatment
The Drug Safety Research Unit (DSRU), based in Southampton, UK, has found a ‘favourable’ profile for Gilead’s antiviral drug remdesivir in COVID-19 after conducting a systematic benefit-risk analysis.